



Innspill EFSA net 12/02-09

Maislinje 98140
EFSA/GMO/UK/2008/53

COMMENTS OR OBJECTIONS TO THE PLACING ON THE MARKET OF A GMO UNDER REGULATION 1829/2003

D, 07.03

Selection of compounds for analysis.

The GMO panel of The Norwegian Scientific Committee for Food Safety (FG3) is of the opinion that key nutrients and the various components listed in the OECD consensus document should be analysed and that their levels should be determined accordingly. If the applicant does not provide the information according to the specifications provided by the OECD, this should be further justified and explained. In relation to the EFSA/GMO/UK/2008/53 notification the Norwegian GMO panel asks for the reason why data on vitamin C is still lacking. For most consumers benefiting from a balanced diet this is probably of minor importance, for vulnerable individuals however (e.g. babies or individuals in developing countries), with a diet consisting predominantly of maize, this may be more relevant.

In the Technical Dossier in Table 14a the range of NAG is about 10^{-3} smaller than the other ranges. Why?

D, 07.08 Toxicology

Acute oral mouse toxicity assessment. On page 40 in the Technical Dossier it is stated that the dose of ZM-HRA protein is 582 mg/kg. In Annex 21, ZM-HRA: Acute oral toxicity study in mice (PHI-2006-009), the dose of ZM-HRA protein is 2000 mg/kg, corresponding to 1648 mg ZM-HRA protein/kg body weight. Which dose is correct?